Arcus Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

RCUS$18.95+3.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In millions, except per share amounts)

	September 30,2024	December 31,2023
ASSETS
Current assets:
Cash and cash equivalents	$201	$127
Marketable securities	888	632
Receivable from collaboration partners ($2 and $20 from a related party)	16	38
Prepaid expenses and other current assets	22	34
Total current assets	1,127	831
Long-term marketable securities	2	107
Property and equipment, net	48	51
Other noncurrent assets ($— and $6 from a related party)	75	106
Total assets	$1,252	$1,095
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$13	$17
Deferred revenue ($93 and $84 to a related party)	105	91
Other current liabilities	97	76
Total current liabilities	215	184
Deferred revenue, noncurrent ($262 and $291 to a related party)	289	307
Long-term debt	47	—
Other noncurrent liabilities	136	142
Commitments
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 91.5 shares in 2024 and 75.5 shares in 2023 issued and outstanding	1,602	1,311
Accumulated deficit	(1,038)	(849)
Accumulated other comprehensive loss	1	—
Total stockholders’ equity	565	462
Total liabilities and stockholders’ equity	$1,252	$1,095

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.